Humeral Cortical Ossific Density: Assessment, Factors & Clinical Significance

Ossific density along the humeral cortex reflects the bone mineral content (BMC) per unit volume of the compact (cortical) bone of the humerus (upper arm). It is a surrogate for bone strength and fracture resistance at that site.

Determinants

FactorEffect on Cortical Density
AgePeaks ~25–30 yr (peak bone mass); gradual decline thereafter; accelerated post-menopause (women) and >70 yr (men).
SexMen > women (larger bones, higher peak mass); women lose faster after menopause.
GeneticsLRP5, WNT16, ESR1, RANKL/OPG variants explain 50–80% of BMD variance.
NutritionCalcium (1000–1200 mg/d), Vitamin D (800–2000 IU/d), protein, vitamin K2, magnesium.
Mechanical loadingWeight-bearing & resistance exercise → Wolff's law adaptation; disuse → rapid loss.
HormonesEstrogen, testosterone, IGF-1, PTH (intermittent anabolic, chronic catabolic), thyroid hormone.
MedicationsGlucocorticoids (↓), anticonvulsants (↓), PPIs (mild ↓), bisphosphonates/denosumab/romosozumab (↑).
DiseaseRA, IBD, celiac, hyperparathyroidism, multiple myeloma, diabetes (↓ bone quality).

Assessment Methods

  • DXA (peripheral) – Distal radius/ulna; correlates with humeral cortex.
  • HR-pQCT – High-resolution peripheral quantitative CT; 3D microarchitecture (cortical thickness, porosity, trabecular BV/TV) at distal radius/tibia; research gold standard.
  • QCT – Volumetric BMD; separates cortical vs trabecular.
  • Plain radiograph – Cortical thickness index (metacarpal/humeral); low sensitivity.

Clinical Significance

  • Low humeral cortical density → ↑ risk of proximal humerus fracture (common in elderly falls).
  • Guides osteoporosis treatment thresholds (FRAX® with BMD).
  • Monitors therapy response (bisphosphonates ↑ cortical density over 1–2 years).
  • Preoperative planning for shoulder arthroplasty, fracture fixation.

Bones, Joints & Muscles - Related Articles